ABIVAX Investor Relations Material
Latest events
H2 2023
ABIVAX
Q1 2025
2 Jun, 2025
Corporate Presentation
2 Jun, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ABIVAX Société Anonyme
Access all reports
ABIVAX Société Anonyme is a clinical-stage biotechnology company that focuses on developing therapeutics designed to modulate the body's natural immune regulatory mechanisms. The company is primarily engaged in advancing its lead drug candidate, obefazimod, which is currently undergoing clinical trials aimed at treating moderately to severely active ulcerative colitis. Additionally, ABIVAX is exploring obefazimod's potential in treating other chronic inflammatory diseases, including Crohn's disease, through ongoing clinical trials and research initiatives. The company is headquartered in Paris, France, and its shares are listed on both the Nasdaq and the Euronext Paris.
Key slides for ABIVAX Société Anonyme
Corporate Presentation
ABIVAX Société Anonyme
Corporate Presentation
ABIVAX Société Anonyme
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
ABVX
Country
🇫🇷 France